# A Study of AC-101 Tablets in Participants With Moderate to Severe Active Ulcerative Colitis

> **NCT07083193** · PHASE1,PHASE2 · RECRUITING · sponsor: **Accro Bioscience (Suzhou) Limited** · enrollment: 24 (estimated)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** AC-101

## Key facts

- **NCT ID:** NCT07083193
- **Lead sponsor:** Accro Bioscience (Suzhou) Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-20
- **Primary completion:** 2026-09-30
- **Final completion:** 2027-04-30
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2025-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07083193

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07083193, "A Study of AC-101 Tablets in Participants With Moderate to Severe Active Ulcerative Colitis". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07083193. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*